Next Article in Journal
Untargeted NMR Spectroscopic Analysis of the Metabolic Variety of New Apple Cultivars
Next Article in Special Issue
The Metabolic Implications of Glucocorticoids in a High-Fat Diet Setting and the Counter-Effects of Exercise
Previous Article in Journal
NMR Chemical Shift Ranges of Urine Metabolites in Various Organic Solvents
Previous Article in Special Issue
Impact of Glucocorticoid Excess on Glucose Tolerance: Clinical and Preclinical Evidence
Open AccessArticle

Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases

Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo 143-8541, Japan
Author to whom correspondence should be addressed.
Academic Editor: Michael C. Riddell
Metabolites 2016, 6(3), 28;
Received: 28 July 2016 / Revised: 8 September 2016 / Accepted: 13 September 2016 / Published: 16 September 2016
(This article belongs to the Special Issue Glucocorticoids and Energy Metabolism)
Adipokines are important regulators of several processes, including inflammation and atherosclerosis. In patients with systemic autoimmune diseases, atherosclerosis is accelerated with higher cardiovascular morbidity and mortality. We prospectively investigated the association of adipokines and glucocorticoid therapy with progression of premature atherosclerosis in 38 patients starting glucocorticoid therapy for systemic autoimmune diseases. To detect premature atherosclerosis, carotid ultrasonography was performed at initiation of glucocorticoid therapy and after a mean three-year follow-up period. The ankle-brachial pressure index and cardio-ankle vascular index (CAVI) were measured. Serum adipokine levels were determined with enzyme-linked immunosorbent assay kits. Twenty-three patients (60.5%) had carotid artery plaque at baseline. The carotid artery intima-media thickness (IMT) increased significantly during follow-up. Glucocorticoids reduced the serum resistin level, while increasing serum leptin and high molecular weight-adiponectin. There was slower progression of atherosclerosis (carotid IMT and CAVI) at follow-up in patients with greater reduction of serum resistin and with higher cumulative prednisolone dose. In conclusion, progression of premature atherosclerosis occurred at an early stage of systemic autoimmune diseases before initiation of glucocorticoid therapy. Since resistin, an inflammation and atherosclerosis related adipokine, is reduced by glucocorticoids, glucocortidoid therapy may not accelerate atherosclerosis in patients with systemic autoimmune diseases. View Full-Text
Keywords: adipokines; resistin; atherosclerosis; glucocorticoid; systemic autoimmune diseases adipokines; resistin; atherosclerosis; glucocorticoid; systemic autoimmune diseases
Show Figures

Figure 1

MDPI and ACS Style

Tanaka, N.; Masuoka, S.; Kusunoki, N.; Nanki, T.; Kawai, S. Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases. Metabolites 2016, 6, 28.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop